X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15049) 15049
Newsletter (175) 175
Book Chapter (8) 8
Newspaper Article (7) 7
Publication (7) 7
Magazine Article (4) 4
Book / eBook (3) 3
Book Review (3) 3
Government Document (3) 3
Conference Proceeding (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (8649) 8649
cyclophosphamide - pharmacology (7043) 7043
science & technology (6723) 6723
life sciences & biomedicine (6523) 6523
humans (6331) 6331
female (6258) 6258
male (5650) 5650
mice (5353) 5353
cyclophosphamide (4344) 4344
cyclophosphamide - administration & dosage (3245) 3245
oncology (2677) 2677
middle aged (2519) 2519
adult (2400) 2400
rats (2320) 2320
antineoplastic combined chemotherapy protocols - therapeutic use (2209) 2209
cyclophosphamide - therapeutic use (2017) 2017
pharmacology & pharmacy (1858) 1858
aged (1614) 1614
time factors (1311) 1311
cyclophosphamide - adverse effects (1208) 1208
doxorubicin - administration & dosage (1181) 1181
dose-response relationship, drug (1143) 1143
cyclophosphamide - toxicity (1072) 1072
chemotherapy (1021) 1021
treatment outcome (977) 977
antineoplastic combined chemotherapy protocols - adverse effects (955) 955
breast neoplasms - drug therapy (952) 952
antineoplastic agents - pharmacology (949) 949
cancer (937) 937
mice, inbred c57bl (924) 924
mice, inbred balb c (918) 918
immunosuppression (877) 877
immunosuppressive agents - pharmacology (850) 850
vincristine - administration & dosage (848) 848
immunology (847) 847
adolescent (828) 828
cyclophosphamide - analogs & derivatives (772) 772
combined modality therapy (709) 709
hematology (697) 697
antineoplastic combined chemotherapy protocols - administration & dosage (686) 686
toxicology (678) 678
research (659) 659
t-lymphocytes - immunology (639) 639
research article (635) 635
spleen - immunology (588) 588
drug administration schedule (573) 573
cells, cultured (570) 570
prednisone - administration & dosage (560) 560
prognosis (552) 552
bone marrow - drug effects (549) 549
disease models, animal (545) 545
child (542) 542
mice, inbred strains (528) 528
medicine, research & experimental (524) 524
research & experimental medicine (524) 524
bone marrow transplantation (515) 515
transplantation, homologous (509) 509
antineoplastic agents - therapeutic use (499) 499
cyclophosphamide - metabolism (499) 499
analysis (497) 497
care and treatment (491) 491
disease-free survival (483) 483
spleen - cytology (479) 479
fluorouracil - administration & dosage (476) 476
etoposide - administration & dosage (475) 475
methotrexate - administration & dosage (471) 471
bone marrow cells (459) 459
antibody formation - drug effects (457) 457
breast cancer (455) 455
drug therapy, combination (452) 452
breast neoplasms - pathology (448) 448
survival analysis (442) 442
neoplasm transplantation (437) 437
medicine & public health (416) 416
antineoplastic agents (412) 412
drug synergism (406) 406
immunosuppressive agents - therapeutic use (406) 406
kinetics (406) 406
health aspects (397) 397
spleen - drug effects (396) 396
transplantation (396) 396
hematopoietic stem cells - drug effects (388) 388
antineoplastic agents, alkylating - pharmacology (386) 386
pharmacology (381) 381
survival rate (381) 381
follow-up studies (376) 376
rats, inbred strains (375) 375
in vitro techniques (374) 374
antineoplastic combined chemotherapy protocols - pharmacology (373) 373
apoptosis (373) 373
cell biology (369) 369
cell survival - drug effects (366) 366
leukocyte count (360) 360
cisplatin - administration & dosage (358) 358
child, preschool (357) 357
cell line, tumor (356) 356
rats, wistar (354) 354
aged, 80 and over (353) 353
immunotherapy (353) 353
neoplasm staging (353) 353
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14149) 14149
German (425) 425
Russian (352) 352
Japanese (275) 275
Chinese (151) 151
French (101) 101
Italian (63) 63
Spanish (42) 42
Polish (41) 41
Portuguese (32) 32
Czech (13) 13
Slovak (6) 6
Ukrainian (5) 5
Dutch (4) 4
Hungarian (3) 3
Romanian (3) 3
Hebrew (2) 2
Norwegian (2) 2
Bulgarian (1) 1
Croatian (1) 1
Korean (1) 1
Persian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Letters, ISSN 0304-3835, 2016, Volume 383, Issue 2, pp. 309 - 317
Abstract In previous studies we demonstrated that targeting the nuclear exporter protein exportin-1 (CRM1/XPO1) by a selective inhibitor of nuclear export... 
Hematology, Oncology and Palliative Medicine | NHL | XPO1 | Selective inhibitors of nuclear export | SINE | CRM1 | Exportin-1 | Life Sciences & Biomedicine | Oncology | Science & Technology | Vincristine - pharmacology | TOR Serine-Threonine Kinases - metabolism | Transcription Factor RelA - antagonists & inhibitors | Apoptosis - drug effects | Humans | Lymphoma, Non-Hodgkin - enzymology | Lymphoma, Non-Hodgkin - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | TOR Serine-Threonine Kinases - antagonists & inhibitors | Dexamethasone - pharmacology | Time Factors | Oxadiazoles - pharmacology | Acrylamides - pharmacology | Lymphoma, Non-Hodgkin - drug therapy | Cell Survival - drug effects | Hydrazines - pharmacology | Everolimus - pharmacology | Mice, SCID | Mice, Inbred ICR | Drug Synergism | Triazoles - pharmacology | Xenograft Model Antitumor Assays | Animals | Karyopherins - metabolism | Signal Transduction - drug effects | Transcription Factor RelA - metabolism | Tumor Burden - drug effects | Active Transport, Cell Nucleus - drug effects | Cyclophosphamide - pharmacology | Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors | Cell Line, Tumor | Prednisone - pharmacology | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Karyopherins - antagonists & inhibitors | Doxorubicin - pharmacology | Receptors, Cytoplasmic and Nuclear - metabolism | International trade | Cyclophosphamide | Care and treatment | Dexamethasone | Analysis | Lymphomas | Prednisone | Exports | Steroids | Cancer | Drugs
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 2004, Volume 96, Issue 10, pp. 739 - 749
Journal Article
PloS one, ISSN 1932-6203, 12/2014, Volume 9, Issue 12, p. e111840
... transduction and chromatin modification has been facilitated by interfacing the sciences of chemical biology and pharmacology [5], [6]. For example, the availability... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | Neoplasm Transplantation | Vincristine - pharmacology | Humans | Receptors, Glucocorticoid - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Receptors, Glucocorticoid - agonists | Dexamethasone - pharmacology | Female | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Drug Evaluation, Preclinical | Lymphoma, Non-Hodgkin - drug therapy | Enhancer of Zeste Homolog 2 Protein - metabolism | Random Allocation | Mice, SCID | Prednisolone - pharmacology | Animals | Cyclophosphamide - pharmacology | Lymphoma, Non-Hodgkin - metabolism | Cell Line, Tumor | Glucocorticoids - pharmacology | Prednisone - pharmacology | Doxorubicin - pharmacology | Pyridones - pharmacology | Care and treatment | Corticosteroids | Fluocinolone acetonide | Central nervous system depressants | Analysis | Histones | Models | Non-Hodgkin's lymphomas | Immunosuppressive agents | Steroids | Cancer | Enzymes | Dexamethasone | Glucocorticoids | Research & development--R&D | Gene expression | Lymphoma | Anticancer properties | Signal transduction | Cell growth | Inhibitors | Lymphomas | Mutation | Prednisolone | Apoptosis | Research & development | R&D
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 8/2011, Volume 68, Issue 2, pp. 445 - 455
The natural flavonoid fisetin was recently identified as a lead compound that stabilizes endothelial cell microtubules. In this study, we investigated the... 
Fisetin | Lewis lung carcinoma | Angiogenesis | Antitumour activity | Cyclophosphamide | Medicine & Public Health | Cancer Research | Oncology | Cytotoxicity | EA·hy 926 endothelial cells | Pharmacology/Toxicology | Flavonoid | EA•hy 926 endothelial cells | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | NIH 3T3 Cells | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Tubulin Modulators - pharmacology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - pharmacology | Flavonoids - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Flavonoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Flavonoids - administration & dosage | Tubulin Modulators - administration & dosage | Female | Flavonoids - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Angiogenesis Inhibitors - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Cell Line | Cell Survival - drug effects | Tubulin Modulators - adverse effects | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Tubulin Modulators - therapeutic use | Carcinoma, Lewis Lung - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Cell Movement - drug effects | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endothelial Cells - cytology | Neovascularization, Pathologic - drug therapy | Cyclophosphamide - pharmacology | Carcinoma, Lewis Lung - pathology | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Alkylating - adverse effects | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Endothelial Cells - drug effects | Antimitotic agents | Flavonoids | Flavones | Lung cancer | Bioflavonoids | Accountants | Drug therapy, Combination | Universities and colleges | Antineoplastic agents | Endothelium | Tumors | Index Medicus | cytology | Antineoplastic Agents, Phytogenic | pathology | Cell Proliferation | Endothelial Cells | Tubulin Modulators | Neovascularization, Pathologic | fisetin | administration & dosage | pharmacology | flavonoid | Carcinoma, Lewis Lung | Antineoplastic Agents, Alkylating | cytotoxicity | drug therapy | Cell Survival | angiogenesis | Antineoplastic Combined Chemotherapy Protocols | drug effects | Tumor Burden | Angiogenesis Inhibitors | EA.hy 926 | Cell Cycle | antitumour activity | adverse effects | therapeutic use | Cell Movement
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 0027-8424, 11/2010, Volume 107, Issue 44, pp. 19084 - 19089
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 9, pp. 1080 - 1088
Highlights • PTCL has a poor prognosis; existing therapies are insufficient. • We summarize current evidence on novel therapies for relapsed/refractory PTCL. •... 
Hematology, Oncology and Palliative Medicine | Antifolate | Nucleoside analog | Histone deacetylase inhibitor | Fusion protein | Peripheral T-cell lymphoma | Immunomodulatory agent | Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Folic Acid Antagonists - therapeutic use | Stem Cell Transplantation | Topoisomerase Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Diphtheria Toxin - therapeutic use | Topoisomerase Inhibitors - therapeutic use | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Depsipeptides - therapeutic use | Prednisolone - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Alemtuzumab | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Vincristine - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Lymphoma, T-Cell, Peripheral - therapy | Thalidomide - therapeutic use | Folic Acid Antagonists - pharmacology | Care and treatment | Lymphomas | T cells | Health aspects
Journal Article
Experimental Hematology, ISSN 0301-472X, 2017, Volume 52, pp. 65 - 71
Drug interactions may dictate the failure or success of a treatment. Patients undergoing hematopoietic stem cell transplantation (HSCT) are exposed to various... 
Hematology, Oncology and Palliative Medicine | Advanced Basic Science | Life Sciences & Biomedicine | Hematology | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Cyclophosphamide - analogs & derivatives | Flow Cytometry - methods | Fluoresceins - metabolism | Humans | Ethacrynic Acid - pharmacology | Antineoplastic Agents, Alkylating - pharmacology | Chlorambucil - pharmacology | Ketoconazole - pharmacology | Drug Interactions | Everolimus - pharmacokinetics | Ethacrynic Acid - pharmacokinetics | Biological Transport - drug effects | Melphalan - pharmacology | Busulfan - pharmacology | Cell Survival - drug effects | Fluoresceins - chemistry | Reproducibility of Results | Busulfan - pharmacokinetics | Everolimus - pharmacology | Chlorambucil - pharmacokinetics | Ketoconazole - pharmacokinetics | Antineoplastic Agents, Alkylating - pharmacokinetics | Sirolimus - pharmacokinetics | Sirolimus - pharmacology | Cyclophosphamide - pharmacology | Cell Line, Tumor | Melphalan - pharmacokinetics | Cyclophosphamide - pharmacokinetics | Multidrug Resistance-Associated Proteins - metabolism | Antimitotic agents | Complications and side effects | Chemotherapy | Leukemia | Drug interactions | Lymphomas | Transplantation | Drug therapy, Combination | Antineoplastic agents | Ethacrynic acid | Hematopoietic stem cells | Cancer | flow cytometry | drug interactions | carboxyfluorescein | drug transporter | drug efflux method | stem cell transplantation
Journal Article